Trial Outcomes & Findings for Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms (NCT NCT06185985)

NCT ID: NCT06185985

Last Updated: 2026-03-27

Results Overview

The Adult ADHD Investigator Symptom Rating Scale (AISRS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The AISRS consists of 18 items that directly correspond to the 18 symptoms of ADHD per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). The scale is subdivided into two subscales: Inattention (IA; 9 items) and Hyperactivity/Impulsivity (HI; 9 items). The clinician/investigator rates the subject on each item using a 4-point scale, where 0=none, 1=mild, 2=moderate, and 3=severe. The sum of the ratings of all 18 items yields the raw Total score (range: 0-54; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline Total Score (\<0) represents a better outcome.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

161 participants

Primary outcome timeframe

Baseline and Week 4, 9, and 14

Results posted on

2026-03-27

Participant Flow

Participant milestones

Participant milestones
Measure
Open-Label Treatment
SPN-812 (200mg to 600mg once daily) for up to 14 weeks Qelbree (viloxazine extended-release capsules)
Overall Study
NOT COMPLETED
57
Overall Study
STARTED
161
Overall Study
COMPLETED
104

Reasons for withdrawal

Reasons for withdrawal
Measure
Open-Label Treatment
SPN-812 (200mg to 600mg once daily) for up to 14 weeks Qelbree (viloxazine extended-release capsules)
Overall Study
Adverse Event
24
Overall Study
Withdrawal by Subject
2
Overall Study
Lack of Efficacy
1
Overall Study
Lost to Follow-up
14
Overall Study
Noncompliance With Study Procedures
11
Overall Study
Other, Multiple Categories
5

Baseline Characteristics

Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Open-Label Treatment
n=161 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks Qelbree (viloxazine extended-release capsules)
Age, Continuous
39.4 years
STANDARD_DEVIATION 10.64 • n=56 Participants
Age, Customized
Between 18 and 29 years
29 Participants
n=56 Participants
Age, Customized
Between 30 and 39 years
56 Participants
n=56 Participants
Age, Customized
Between 40 and 49 years
49 Participants
n=56 Participants
Age, Customized
Between 50 and 59 years
20 Participants
n=56 Participants
Age, Customized
>=60 years
7 Participants
n=56 Participants
Sex: Female, Male
Female
122 Participants
n=56 Participants
Sex: Female, Male
Male
39 Participants
n=56 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
11 Participants
n=56 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
150 Participants
n=56 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=56 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=56 Participants
Race (NIH/OMB)
Asian
7 Participants
n=56 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=56 Participants
Race (NIH/OMB)
Black or African American
11 Participants
n=56 Participants
Race (NIH/OMB)
White
129 Participants
n=56 Participants
Race (NIH/OMB)
More than one race
12 Participants
n=56 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=56 Participants
Region of Enrollment
United States
161 participants
n=56 Participants
Adult ADHD Investigator Symptom Rating Scale (AISRS)
37.5 score on a scale
STANDARD_DEVIATION 6.58 • n=56 Participants

PRIMARY outcome

Timeframe: Baseline and Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Adult ADHD Investigator Symptom Rating Scale (AISRS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The AISRS consists of 18 items that directly correspond to the 18 symptoms of ADHD per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). The scale is subdivided into two subscales: Inattention (IA; 9 items) and Hyperactivity/Impulsivity (HI; 9 items). The clinician/investigator rates the subject on each item using a 4-point scale, where 0=none, 1=mild, 2=moderate, and 3=severe. The sum of the ratings of all 18 items yields the raw Total score (range: 0-54; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline Total Score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score by Visit.
Change from Baseline score; Week 14
-17.3 score on a scale
Standard Deviation 11.34
Change From Baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score by Visit.
Raw score; Baseline
37.5 score on a scale
Standard Deviation 6.53
Change From Baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score by Visit.
Change from Baseline score; Week 4
-12.3 score on a scale
Standard Deviation 9.96
Change From Baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score by Visit.
Change from Baseline score; Week 9
-14.3 score on a scale
Standard Deviation 10.20

SECONDARY outcome

Timeframe: Baseline and Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Adult ADHD Investigator Symptom Rating Scale (AISRS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The AISRS consists of 18 items that directly correspond to the 18 symptoms of ADHD per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). The scale is subdivided into two subscales: Inattention (IA; 9 items) and Hyperactivity/Impulsivity (HI; 9 items). The clinician/investigator rates the subject on each item using a 4-point scale, where 0=none, 1=mild, 2=moderate, and 3=severe. The sum of the ratings of the 9 IA items yields the raw IA subscale score (range: 0-27; the higher the IA Subscale score, the more severe the IA symptoms). Post-baseline raw Subscale score is converted to a change from baseline Subscale score. A lower change from baseline Subscale Score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) Inattention Subscale Score by Visit.
Raw score; Baseline
20.4 score on a scale
Standard Deviation 3.34
Change From Baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) Inattention Subscale Score by Visit.
Change from Baseline score; Week 4
-6.8 score on a scale
Standard Deviation 5.21
Change From Baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) Inattention Subscale Score by Visit.
Change from Baseline score; Week 9
-7.6 score on a scale
Standard Deviation 5.57
Change From Baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) Inattention Subscale Score by Visit.
Change from Baseline score; Week 14
-8.9 score on a scale
Standard Deviation 6.04

SECONDARY outcome

Timeframe: Baseline and Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Adult ADHD Investigator Symptom Rating Scale (AISRS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The AISRS consists of 18 items that directly correspond to the 18 symptoms of ADHD per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). The scale is subdivided into two subscales: Inattention (IA; 9 items) and Hyperactivity/Impulsivity (HI; 9 items). The clinician/investigator rates the subject on each item using a 4-point scale, where 0=none, 1=mild, 2=moderate, and 3=severe. The sum of the ratings of the 9 HI items yields the raw HI subscale score (range: 0-27; the higher the HI Subscale score, the more severe the HI symptoms). Post-baseline raw Subscale score is converted to a change from baseline Subscale score. A lower change from baseline Subscale Score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) Hyperactivity/Impulsivity Subscale Score by Visit.
Raw score; Baseline
17.1 score on a scale
Standard Deviation 4.24
Change From Baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) Hyperactivity/Impulsivity Subscale Score by Visit.
Change from Baseline score; Week 4
-5.6 score on a scale
Standard Deviation 5.51
Change From Baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) Hyperactivity/Impulsivity Subscale Score by Visit.
Change from Baseline score; Week 9
-6.8 score on a scale
Standard Deviation 5.67
Change From Baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) Hyperactivity/Impulsivity Subscale Score by Visit.
Change from Baseline score; Week 14
-8.4 score on a scale
Standard Deviation 6.20

SECONDARY outcome

Timeframe: Baseline and Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) is an ADHD-specific rating scale designed and validated to assess self-ratings of current ADHD symptomatology in adults. The ASRSv1.1-SC consists of 18 items that directly correspond to the 18 symptoms of ADHD per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). The scale is subdivided into two subscales: Inattention (IA; 9 items) and Hyperactivity/Impulsivity (HI; 9 items). The subject rates the frequency of each item on a 5-point scale, where 0=never, 1=rarely, 2=sometimes, 3=often, and 4=very often. The sum of the ratings of all 18 items yields the raw Total score (range: 0-72; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline Total Score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) Total Score by Visit.
Raw score; Baseline
53.5 score on a scale
Standard Deviation 8.51
Change From Baseline in Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) Total Score by Visit.
Change from Baseline score; Week 4
-18.5 score on a scale
Standard Deviation 13.80
Change From Baseline in Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) Total Score by Visit.
Change from Baseline score; Week 9
-22.7 score on a scale
Standard Deviation 15.57
Change From Baseline in Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) Total Score by Visit.
Change from Baseline score; Week 14
-28.4 score on a scale
Standard Deviation 14.89

SECONDARY outcome

Timeframe: Baseline and Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) is an ADHD-specific rating scale designed and validated to assess self-ratings of current ADHD symptomatology in adults. The ASRSv1.1-SC consists of 18 items that directly correspond to the 18 symptoms of ADHD per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). The scale is subdivided into two subscales: Inattention (IA; 9 items) and Hyperactivity/Impulsivity (HI; 9 items). The subject rates the frequency of each item on a 5-point scale, where 0=never, 1=rarely, 2=sometimes, and 3=often, and 4=very often. The sum of the ratings of the 9 IA items yields the raw IA subscale score (range: 0-36; the higher the IA Subscale score, the more severe the IA symptoms). Post-baseline raw Subscale score is converted to a change from baseline Subscale score. A lower change from baseline Subscale Score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in the Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) Inattention Subscale Score by Visit.
Raw score; Baseline
29.1 score on a scale
Standard Deviation 4.16
Change From Baseline in the Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) Inattention Subscale Score by Visit.
Change from Baseline score; Week 4
-9.7 score on a scale
Standard Deviation 7.75
Change From Baseline in the Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) Inattention Subscale Score by Visit.
Change from Baseline score; Week 9
-12.0 score on a scale
Standard Deviation 8.61
Change From Baseline in the Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) Inattention Subscale Score by Visit.
Change from Baseline score; Week 14
-14.9 score on a scale
Standard Deviation 7.83

SECONDARY outcome

Timeframe: Baseline and Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) is an ADHD-specific rating scale designed and validated to assess self-ratings of current ADHD symptomatology in adults. The ASRSv1.1-SC consists of 18 items that directly correspond to the 18 symptoms of ADHD per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). The scale is subdivided into two subscales: Inattention (IA; 9 items) and Hyperactivity/Impulsivity (HI; 9 items). The subject rates the frequency of each item on a 5-point scale, where 0=never, 1=rarely, 2=sometimes, and 3=often, and 4=very often. The sum of the ratings of the 9 HI items yields the raw HI subscale score (range: 0-36; the higher the HI Subscale score, the more severe the HI symptoms). Post-baseline raw Subscale score is converted to a change from baseline Subscale score. A lower change from baseline Subscale Score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in the Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) Hyperactivity/Impulsivity Subscale Score by Visit.
Raw score; Baseline
24.4 score on a scale
Standard Deviation 5.71
Change From Baseline in the Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) Hyperactivity/Impulsivity Subscale Score by Visit.
Change from Baseline score; Week 4
-8.8 score on a scale
Standard Deviation 6.80
Change From Baseline in the Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) Hyperactivity/Impulsivity Subscale Score by Visit.
Change from Baseline score; Week 9
-10.7 score on a scale
Standard Deviation 7.83
Change From Baseline in the Adult ADHD Self-Report Scale (v1.1) Symptoms Checklist (ASRSv1.1-SC) Hyperactivity/Impulsivity Subscale Score by Visit.
Change from Baseline score; Week 14
-13.5 score on a scale
Standard Deviation 7.82

SECONDARY outcome

Timeframe: Baseline and Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Clinical Global Impression of Severity (CGI-S) scale is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Asymptomatic, no symptoms; 2 = Borderline, 3 = Mild, 4 = Moderate, 5 = Marked, 6 = Severe, and 7 = Among the most extreme (the higher the score, the more severe the symptoms). Post-baseline (raw) CGI-S scores are converted to a change from baseline score. A lower change from baseline CGI-S score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Score by Visit
Raw score; Baseline
4.7 score on a scale
Standard Deviation 0.57
Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Score by Visit
Change from Baseline score; Week 4
-1.0 score on a scale
Standard Deviation 0.80
Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Score by Visit
Change from Baseline score; Week 9
-1.2 score on a scale
Standard Deviation 0.85
Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Score by Visit
Change from Baseline score; Week 14
-1.4 score on a scale
Standard Deviation 1.06

SECONDARY outcome

Timeframe: Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Clinical Global Impression of Change (CGI-C) scale is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". A CGI-C score \<4 represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
The Clinical Global Impression of Change (CGI-C) Score by Visit
Raw score; Week 4
2.7 score on a scale
Standard Deviation 0.81
The Clinical Global Impression of Change (CGI-C) Score by Visit
Raw score; Week 9
2.6 score on a scale
Standard Deviation 1.09
The Clinical Global Impression of Change (CGI-C) Score by Visit
Raw score; Week 14
2.3 score on a scale
Standard Deviation 0.97

SECONDARY outcome

Timeframe: Baseline and Week 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item investigator-rated diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders and is designed to be sensitive to changes elicited by treatment. A Structured Interview Guide for the MADRS (SIGMA) was developed to improve inter- and intra-rater consistency and improve reliability. The clinician rates each of the 10 items (symptoms) on a 7-point scale \[0-6 continuum, where 0=no abnormality to 6=severe\]. The sum of the ratings of all 10 items yields the raw Total score (range: 0-60; the higher the Total score, the more severe the depression symptoms). The post-baseline raw Total score is converted to a change from baseline Total score. A lower change from baseline Total Score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in the Montgomery and Åsberg Depression Rating Scale (MADRS) Total Score at Week 14/End of Study
Raw score; Baseline
30.3 score on a scale
Standard Deviation 3.12
Change From Baseline in the Montgomery and Åsberg Depression Rating Scale (MADRS) Total Score at Week 14/End of Study
Change from Baseline score; Week 14
-15.5 score on a scale
Standard Deviation 7.12

SECONDARY outcome

Timeframe: Baseline and Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Patient Health Questionnaire 8-item (PHQ-8) is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression per diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders. The PHQ-8 has been validated as a diagnostic and severity measure for depressive disorders in large clinical studies. The patient rates each item on 4-point scale (0-3), where 0 = not at all; 1 = several days; 2 = more than half the days; and 3 = nearly every day). The sum of the ratings of all 8 items yields the raw Total score (range: 0-24; the higher the Total score, the more severe the depression symptoms). The post-baseline raw Total score is converted to a change from baseline Total score. A lower change from baseline Total Score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in Patient Health Questionnaire 8-item (PHQ-8) Total Score by Visit
Raw score; Baseline
16.4 score on a scale
Standard Deviation 4.16
Change From Baseline in Patient Health Questionnaire 8-item (PHQ-8) Total Score by Visit
Change from Baseline score; Week 4
-7.2 score on a scale
Standard Deviation 5.92
Change From Baseline in Patient Health Questionnaire 8-item (PHQ-8) Total Score by Visit
Change from Baseline score; Week 9
-8.8 score on a scale
Standard Deviation 6.54
Change From Baseline in Patient Health Questionnaire 8-item (PHQ-8) Total Score by Visit
Change from Baseline score; Week 14
-10.6 score on a scale
Standard Deviation 5.24

SECONDARY outcome

Timeframe: Baseline and Week 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Hamilton Anxiety Scale (HAM-A) is a 14-item investigator-rated scale developed to assess/measure the severity of an individual's anxiety. The HAM-A has been used to assess severity of anxiety in children, adolescents, and adults in both clinical and research settings. A Structured Interview Guide for the HAM-A (SIGH-A) was developed to improve inter- and intra-rater consistency and improve reliability. The clinician rates each of the 14 items on a 5-point scale (0-4), where 0 = Not present, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very severe. The sum of the ratings of all 14 items yields the raw Total score (range: 0-56; the higher the Total score, the more severe the symptoms of anxiety). The post-baseline raw Total score is converted to a change from baseline Total score. A lower change from baseline Total Score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Week 14
Raw score; Baseline
25.4 score on a scale
Standard Deviation 2.38
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Week 14
Change from Baseline score; Week 14
-14.2 score on a scale
Standard Deviation 5.79

SECONDARY outcome

Timeframe: Baseline and Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Generalized Anxiety Disorder 7-Item (GAD-7) is a self-reported 7-item questionnaire for screening and measuring the severity of generalized anxiety disorder. The subject rates each item on 4-point scale (0-3), where 0 = "Not at all", 1 = "Several days", 2 = "Over half the days", and 3 = "Nearly every day". The sum of the 7 items yields a raw GAD-7 Total score (range between 0 to 21); the higher the Total score, the more severe the symptoms of anxiety. Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline Total score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in General Anxiety Disorder 7-item (GAD-7) Total Score by Visit
Raw score; Baseline
14.4 score on a scale
Standard Deviation 4.54
Change From Baseline in General Anxiety Disorder 7-item (GAD-7) Total Score by Visit
Change from Baseline score; Week 4
-6.1 score on a scale
Standard Deviation 5.67
Change From Baseline in General Anxiety Disorder 7-item (GAD-7) Total Score by Visit
Change from Baseline score; Week 9
-7.2 score on a scale
Standard Deviation 5.94
Change From Baseline in General Anxiety Disorder 7-item (GAD-7) Total Score by Visit
Change from Baseline score; Week 14
-8.5 score on a scale
Standard Deviation 5.33

SECONDARY outcome

Timeframe: Baseline and Week 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) is a 75-item self-rating scale that assesses overall functioning (GEC) and 9 non-overlapping scales among 2 summary index scales (Metacognition Index \[MI\] and Behavioral Regulation Index \[BRI\]) that assess aspects of executive function and problems with self-regulation from the perspective of the individual. Subjects rate each item on a 3-point scale (1=Never, 2=Sometimes, or 3=Often) based on their experience in past month. The sum of 70 items yields the GEC raw score (range: 70-210), which is converted to a T-score (normative population mean=50 and standard deviation=10; T-score ≥ 65 is considered abnormally elevated). The post-baseline GEC T-score is converted to a change from baseline T-score. A lower change from baseline GEC T-score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Global Executive Composite (GEC) T-score at Week 14 (End of Study)
T-score; Baseline
79.9 T-score
Standard Deviation 9.84
Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Global Executive Composite (GEC) T-score at Week 14 (End of Study)
Change from Baseline T-score; Week 14
-16.2 T-score
Standard Deviation 13.75

SECONDARY outcome

Timeframe: Baseline and Week 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) is a 75-item self-rating scale that assesses overall functioning and 9 non-overlapping scales among 2 summary index scales, the Metacognition Index (MI) and the Behavioral Regulation Index (BRI). The BRI captures the ability to maintain appropriate regulatory control of one's own behavior and emotional responses. Subjects rate each item on a 3-point scale (1=Never, 2=Sometimes, or 3=Often) based on their experience in past month. The sum of 30 items yields the BRI raw score (range: 30-90), which is converted to a T-score (normative population mean=50 and standard deviation=10; T-score ≥ 65 is considered abnormally elevated). The post-baseline BRI T-score is converted to a change from baseline T-score. A lower change from baseline BRI T-score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Behavioral Regulation Index (BRI) T-score at Week 14 (End of Study)
T-score; Baseline
71.2 T-score
Standard Deviation 11.85
Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Behavioral Regulation Index (BRI) T-score at Week 14 (End of Study)
Change from Baseline T-score; Week 14
-13.1 T-score
Standard Deviation 12.45

SECONDARY outcome

Timeframe: Baseline and Week 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) is a 75-item self-rating scale that assesses overall functioning and 9 non-overlapping scales among 2 summary index scales, the Metacognition Index (MI) and the Behavioral Regulation Index (BRI). MI reflects individual's ability to problem solve (includes initiate activity, generate ideas, sustain working memory, plan/organize approaches, monitor success/failure, and organize materials/environment). Subjects rate each item on a 3-point scale (1=Never, 2=Sometimes, or 3=Often) based on their experience in past month. The sum of 40 items yields the MI raw score (range: 40-120), which is converted to a T-score (normative population mean=50 and standard deviation=10; T-score ≥ 65 is considered abnormally elevated). The post-baseline MI T-score is converted to a change from baseline T-score. A lower change from baseline MI T-score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Metacognition Index (MI) T-score at Week 14 (End of Study)
T-score; Baseline
82.6 T-score
Standard Deviation 9.19
Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Metacognition Index (MI) T-score at Week 14 (End of Study)
Change from Baseline T-score; Week 14
-16.4 T-score
Standard Deviation 13.79

SECONDARY outcome

Timeframe: Baseline and Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Questionnaire is a self-assessment questionnaire that measures the impact of health problems on work productivity and regular activities based on specific health problem (e.g., ADHD). The WPAI:SHP consists of 6 questions that ask about the number of hours missed from work or regular activities due to the specific health problem. The WPAI:SHP yields 4 scores: absenteeism (percentage of time absent from work), presenteeism (percentage of time impaired/unproductive at work), total work productivity impairment (absenteeism plus presenteeism), and total activity impairment (percentage of time affected outside the workplace); range 0-100%; the higher percentage, the greater the impairment). Post-baseline percentages are converted to a change from baseline percentage. A lower change from baseline Absenteeism percentage (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Absenteeism Percentage by Visit
Raw percentage; Baseline
10.87 percentage
Standard Deviation 15.109
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Absenteeism Percentage by Visit
Change from Baseline percentage; Week 4
-3.20 percentage
Standard Deviation 15.646
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Absenteeism Percentage by Visit
Change from Baseline percentage; Week 9
-6.41 percentage
Standard Deviation 13.903
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Absenteeism Percentage by Visit
Change from Baseline percentage; Week 14
-5.89 percentage
Standard Deviation 20.170

SECONDARY outcome

Timeframe: Baseline and Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Questionnaire is a self-assessment questionnaire that measures the impact of health problems on work productivity and regular activities based on specific health problem (e.g., ADHD). The WPAI:SHP consists of 6 questions that ask about the number of hours missed from work or regular activities due to the specific health problem. The WPAI:SHP yields 4 scores: absenteeism (percentage of time absent from work), presenteeism (percentage of time impaired/unproductive at work), total work productivity impairment (absenteeism plus presenteeism), and total activity impairment (percentage of time affected outside the workplace); range 0-100%; the higher percentage, the greater the impairment). Post-baseline percentages are converted to a change from baseline percentage. A lower change from baseline Presenteeism percentage (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Presenteeism Percentage by Visit
Raw percentage; Baseline
62.66 percentage
Standard Deviation 20.009
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Presenteeism Percentage by Visit
Change from Baseline percentage; Week 4
-19.05 percentage
Standard Deviation 21.013
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Presenteeism Percentage by Visit
Change from Baseline percentage; Week 9
-20.43 percentage
Standard Deviation 25.055
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Presenteeism Percentage by Visit
Change from Baseline percentage; Week 14
-23.08 percentage
Standard Deviation 26.072

SECONDARY outcome

Timeframe: Baseline and Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Questionnaire is a self-assessment questionnaire that measures the impact of health problems on work productivity and regular activities based on specific health problem (e.g., ADHD). The WPAI:SHP consists of 6 questions that ask about the number of hours missed from work or regular activities due to the specific health problem. The WPAI:SHP yields 4 scores: absenteeism (percentage of time absent from work), presenteeism (percentage of time impaired/unproductive at work), total work productivity impairment (absenteeism plus presenteeism), and total activity impairment (percentage of time affected outside the workplace); range 0-100%; the higher percentage, the greater the impairment). Post-baseline percentages are converted to a change from baseline percentage. A lower change from baseline Regular Activity percentage (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Regular Activity Percentage by Visit
Raw percentage; Baseline
75.47 percentage
Standard Error 16.036
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Regular Activity Percentage by Visit
Change from Baseline percentage; Week 4
-23.23 percentage
Standard Error 24.055
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Regular Activity Percentage by Visit
Change from Baseline percentage; Week 9
-29.74 percentage
Standard Error 28.021
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Regular Activity Percentage by Visit
Change from Baseline percentage; Week 14
-36.06 percentage
Standard Error 24.230

SECONDARY outcome

Timeframe: Baseline and Week 4, 9, and 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Questionnaire is a self-assessment questionnaire that measures the impact of health problems on work productivity and regular activities based on specific health problem (e.g., ADHD). The WPAI:SHP consists of 6 questions that ask about the number of hours missed from work or regular activities due to the specific health problem. The WPAI:SHP yields 4 scores: absenteeism (percentage of time absent from work), presenteeism (percentage of time impaired/unproductive at work), total work productivity impairment (absenteeism plus presenteeism), and total activity impairment (percentage of time affected outside the workplace); range 0-100%; the higher percentage, the greater the impairment). Post-baseline percentages are converted to a change from baseline percentage. A lower change from baseline Work Productivity percentage (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Work Productivity Percentage by Visit
Raw percentage; Baseline
65.83 percentage
Standard Deviation 20.712
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Work Productivity Percentage by Visit
Change from Baseline percentage; Week 4
-19.10 percentage
Standard Deviation 21.691
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Work Productivity Percentage by Visit
Change from Baseline percentage; Week 9
-21.22 percentage
Standard Deviation 25.333
Change From Baseline in the Work Productivity and Activity Impairment:Specific Health Problem (WPAI:SHP) Work Productivity Percentage by Visit
Change from Baseline percentage; Week 14
-22.32 percentage
Standard Deviation 26.915

SECONDARY outcome

Timeframe: Baseline and Week 14

Population: Full Analysis Set, defined as a subset of participants in the Safety Population (defined as participants who received at least one dose of study medication) who had a valid AISRS assessment at baseline (prior to first dose) and at least one valid AISRS assessment Postbaseline (after first dose). Due to attrition and/or missing data, the number of participants analyzed at each study visit may be less than the number of participants in the Full Analysis Set.

The Pittsburgh Sleep Quality Index (PSQI) is a validated and effective instrument used to measure the quality and patterns of sleep in adults. The PSQI is a self-rated, 19-item questionnaire out of which generate 7 component scores (or domains): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each component is scored on a 4-point scale based on an individual algorithm; range: 0 to 3, whereby 0=better and 3=worse). The sum of all 7 component scores yields the Global score (range:0 to 21); a global score \>5 is associated with poor sleep quality. A post-baseline raw Global score is converted to a change from baseline Global score. A lower change from baseline Global score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Open-Label Treatment
n=150 Participants
SPN-812 (200mg to 600mg once daily) for up to 14 weeks
Change From Baseline in the Pittsburgh Sleep Quality Index (PSQI) Global Score at Week 14 (End of Study)
Raw score; Baseline
10.8 score on a scale
Standard Deviation 3.29
Change From Baseline in the Pittsburgh Sleep Quality Index (PSQI) Global Score at Week 14 (End of Study)
Change from Baseline score; Week 14
-2.2 score on a scale
Standard Deviation 4.05

Adverse Events

Open-Label Treatment

Serious events: 6 serious events
Other events: 113 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Open-Label Treatment
n=161 participants at risk
SPN-812 (200mg to 600mg once daily) for up to 14 weeks SPN-812: SPN-812 (200mg to 600mg once daily)
Psychiatric disorders
Suicidal ideation
1.2%
2/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)
Endocrine disorders
Addison's disease
0.62%
1/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)
Gastrointestinal disorders
Cyclic vomiting syndrome
0.62%
1/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)
General disorders
Sensation of foreign body
0.62%
1/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)
Investigations
Hepatic enzyme increased
0.62%
1/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)
Nervous system disorders
Migraine
0.62%
1/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)

Other adverse events

Other adverse events
Measure
Open-Label Treatment
n=161 participants at risk
SPN-812 (200mg to 600mg once daily) for up to 14 weeks SPN-812: SPN-812 (200mg to 600mg once daily)
Nervous system disorders
Migraine
6.8%
11/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)
Gastrointestinal disorders
Dry mouth
6.8%
11/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)
Gastrointestinal disorders
Nausea
21.1%
34/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)
Psychiatric disorders
Insomnia
19.3%
31/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)
Gastrointestinal disorders
Constipation
13.7%
22/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)
Nervous system disorders
Headache
10.6%
17/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)
General disorders
Fatigue
9.3%
15/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)
Nervous system disorders
Somnolence
8.7%
14/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)
Metabolism and nutrition disorders
Decreased appetite
7.5%
12/161 • up to 14 weeks
Number of participants is based on Safety Population (defined as participants who took at least one dose of SPN-812)

Additional Information

Joseph T. Hull, PhD

Supernus Pharmaceuticals

Phone: 240-403-5324

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place